- Home
- BLW vs COGT Comparison
BLW vs COGT Comparison
Compare BLW & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLW
- COGT
- Stock Information
- Founded
- BLW 2003
- COGT 2014
- Country
- BLW United States
- COGT United States
- Employees
- BLW N/A
- COGT N/A
- Industry
- BLW Other Consumer Services
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- BLW Consumer Discretionary
- COGT Health Care
- Exchange
- BLW Nasdaq
- COGT Nasdaq
- Market Cap
- BLW 518.5M
- COGT 545.3M
- IPO Year
- BLW N/A
- COGT 2018
- Fundamental
- Price
- BLW $14.00
- COGT $4.81
- Analyst Decision
- BLW
- COGT Buy
- Analyst Count
- BLW 0
- COGT 7
- Target Price
- BLW N/A
- COGT $14.00
- AVG Volume (30 Days)
- BLW 85.9K
- COGT 1.3M
- Earning Date
- BLW 01-01-0001
- COGT 05-06-2025
- Dividend Yield
- BLW 8.83%
- COGT N/A
- EPS Growth
- BLW N/A
- COGT N/A
- EPS
- BLW 1.81
- COGT N/A
- Revenue
- BLW N/A
- COGT N/A
- Revenue This Year
- BLW N/A
- COGT N/A
- Revenue Next Year
- BLW N/A
- COGT N/A
- P/E Ratio
- BLW $7.73
- COGT N/A
- Revenue Growth
- BLW N/A
- COGT N/A
- 52 Week Low
- BLW $12.35
- COGT $3.72
- 52 Week High
- BLW $14.26
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- BLW 60.94
- COGT 44.64
- Support Level
- BLW $13.82
- COGT $4.55
- Resistance Level
- BLW $13.76
- COGT $5.89
- Average True Range (ATR)
- BLW 0.12
- COGT 0.38
- MACD
- BLW 0.06
- COGT 0.09
- Stochastic Oscillator
- BLW 100.00
- COGT 34.55
About BLW Blackrock Limited Duration Income Trust
Blackrock Ltd Duration Income Trust is a diversified investment fund with an investment objective to provide current income and capital appreciation. The Fund's portfolio normally has an average portfolio duration of less than five years. The Fund may invest directly in such securities or synthetically through the use of derivatives.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.